Keyword: Gilead Sciences

Tesaro has reportedly tried to sell itself before, but to no avail. But its newly lowered share price may be sparking some new buyout interest.

New phase 3b data showed that, with just eight weeks of treatment, Mavyret could cure HCV patients with compensated cirrhosis.

AbbVie inked a deal with the Medicines Patent Pool to boost access to hep C drug Mavyret in nearly 100 low- and middle-income countries and territories.

Express Scripts is rolling out a new formulary to assist drugmakers with lowering list prices.

Pushing to eradicate hepatitis C in England, the NHS is weighing bids for bulk drug buys, but AbbVie has sued over an unfair bidding process.

UnitedHealthcare unveiled a new program to reward patients for choosing a cheaper HIV treatment option, scaring Gilead Sciences investors days later.

Gilead's third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren't convinced.

In a new report, Leerink Partners analyst Geoffrey Porges detailed which "signature" drugs might struggle to grow due to U.S. pricing pressure.

NICE may have rejected it, but thanks to a new discount, Yescarta's beating archrival Kymriah to adult lymphoma patients on England's health service.

Merck lost out when a judge nixed $200 million in patent damages, citing misconduct and fabricated testimony. Now it wants the Supreme Court to intervene.